PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis

Abstract Background Immunotherapy with PD-1/PD-L1 inhibitors has transformed advanced non-small cell lung cancer (NSCLC) treatment, yet optimal strategies for elderly patients remain uncertain. Elderly patients (≥ 65 years) exhibit immune senescence (e.g., T-cell dysfunction, chronic inflammation),...

全面介绍

书目详细资料

Principais autores:	Yunye Mao, An Wang, Xiangwei Ge, Jinzhao Zhai, Yi Hu, Jinliang Wang
格式:	Artigo
语言:	Inglês
出版:	BMC 2025-07-01
丛编:	BMC Pulmonary Medicine
主题:	Elderly patients Advanced non-small cell lung cancer Immunotherapy Immune combination therapy
在线阅读:	https://doi.org/10.1186/s12890-025-03791-x
标签:	添加标签 没有标签, 成为第一个标记此记录!